DE69128476D1 - Adoptive immuntherapie mit interleukin-7 - Google Patents

Adoptive immuntherapie mit interleukin-7

Info

Publication number
DE69128476D1
DE69128476D1 DE69128476T DE69128476T DE69128476D1 DE 69128476 D1 DE69128476 D1 DE 69128476D1 DE 69128476 T DE69128476 T DE 69128476T DE 69128476 T DE69128476 T DE 69128476T DE 69128476 D1 DE69128476 D1 DE 69128476D1
Authority
DE
Germany
Prior art keywords
lymphoid cells
interleukin
individual
specific antigen
adoptive immunotherapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69128476T
Other languages
English (en)
Other versions
DE69128476T2 (de
Inventor
David Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Application granted granted Critical
Publication of DE69128476D1 publication Critical patent/DE69128476D1/de
Publication of DE69128476T2 publication Critical patent/DE69128476T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69128476T 1990-07-26 1991-07-12 Adoptive immuntherapie mit interleukin-7 Expired - Lifetime DE69128476T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/559,001 US5229115A (en) 1990-07-26 1990-07-26 Adoptive immunotherapy with interleukin-7
PCT/US1991/004919 WO1992001459A1 (en) 1990-07-26 1991-07-12 Adoptive immunotherapy with interleukin-7

Publications (2)

Publication Number Publication Date
DE69128476D1 true DE69128476D1 (de) 1998-01-29
DE69128476T2 DE69128476T2 (de) 1998-07-23

Family

ID=24231881

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69128476T Expired - Lifetime DE69128476T2 (de) 1990-07-26 1991-07-12 Adoptive immuntherapie mit interleukin-7

Country Status (16)

Country Link
US (1) US5229115A (de)
EP (1) EP0540599B1 (de)
JP (1) JP3825467B2 (de)
AT (1) ATE161180T1 (de)
AU (1) AU646881B2 (de)
CA (1) CA2087525C (de)
DE (1) DE69128476T2 (de)
DK (1) DK0540599T3 (de)
ES (1) ES2112860T3 (de)
FI (1) FI105045B (de)
GR (1) GR3026358T3 (de)
IE (1) IE912486A1 (de)
IL (1) IL98957A (de)
NO (1) NO930243D0 (de)
NZ (1) NZ239113A (de)
WO (1) WO1992001459A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5728388A (en) * 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
AU6358994A (en) * 1993-03-02 1994-09-26 David S. Terman Method of cancer treatment
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
WO1998016238A2 (en) * 1996-10-11 1998-04-23 The Regents Of The University Of California Cancer immunotherapy using tumor cells combined with mixed lymphocytes
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
JP4741074B2 (ja) 1998-02-24 2011-08-03 シスターズ オブ プロビデンス イン オレゴン Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
HUP0402656A3 (en) 2001-02-20 2012-03-28 Ortho Mcneil Pharm Inc A cell therapy method for the treatment of tumors
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
EP1461422A4 (de) * 2001-11-22 2005-11-16 Medigenes Interleukin-2-gen-transferierte lymphokin-aktivierte killerzellen
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
US9265816B2 (en) 2006-04-10 2016-02-23 Sloan Kettering Institute For Cancer Research Immunogenic WT-1 peptides and methods of use thereof
BRPI0719446A2 (pt) 2006-09-28 2013-12-10 Schering Corp Uso de il-10 peguilada para tratar câncer
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
CA2745603A1 (en) 2008-12-03 2010-06-10 Proyecto De Biomedicina Cima, S.L. Use of phenol soluble modulins for the development of vaccines
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
EP3769782A1 (de) 2013-01-15 2021-01-27 Memorial Sloan Kettering Cancer Center Immunogene wt-1-peptide und verfahren zur verwendung davon
US9844569B2 (en) 2013-03-01 2017-12-19 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor reactive T cells from peripheral blood
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
MX2016005915A (es) 2013-11-11 2016-12-16 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
WO2015131035A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CN107106655A (zh) 2014-10-22 2017-08-29 阿尔莫生物科技股份有限公司 使用白细胞介素‑10治疗疾病和病症的方法
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3302547A1 (de) 2015-05-28 2018-04-11 Armo Biosciences, Inc. Pegyliertes interleukin-10 zur behandlung von krebs
MX2017016134A (es) 2015-06-11 2018-08-15 Lycera Corp Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
WO2017035232A1 (en) 2015-08-25 2017-03-02 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US20210379106A1 (en) * 2018-06-14 2021-12-09 Lixte Biotechnology, Inc. Oxabicycloheptanes for enhancing car t cell function

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4902288A (en) * 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
AU3183089A (en) * 1988-02-11 1989-09-06 Board Of Regents, The University Of Texas System Improved method for treatment of cancer with activated oncolytic leukocytes
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Also Published As

Publication number Publication date
NZ239113A (en) 1997-07-27
DK0540599T3 (da) 1998-08-24
CA2087525C (en) 2006-05-30
GR3026358T3 (en) 1998-06-30
AU8287291A (en) 1992-02-18
US5229115A (en) 1993-07-20
JPH05509093A (ja) 1993-12-16
IE912486A1 (en) 1992-01-29
FI105045B (fi) 2000-05-31
EP0540599B1 (de) 1997-12-17
NO930243L (no) 1993-01-25
IL98957A0 (en) 1992-07-15
DE69128476T2 (de) 1998-07-23
JP3825467B2 (ja) 2006-09-27
FI930206A (fi) 1993-01-19
NO930243D0 (no) 1993-01-25
AU646881B2 (en) 1994-03-10
IL98957A (en) 2000-11-21
FI930206A0 (fi) 1993-01-19
ATE161180T1 (de) 1998-01-15
CA2087525A1 (en) 1992-01-27
ES2112860T3 (es) 1998-04-16
EP0540599A1 (de) 1993-05-12
WO1992001459A1 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
DE69128476T2 (de) Adoptive immuntherapie mit interleukin-7
FI953731A (fi) Menetelmä PRRS-viruksen viljelemiseksi ja sen käyttö rokotteissa
SE8005256L (sv) Framstellningsforfarande
DE69329344T2 (de) Spezifische modulationen des immunsystems
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
FI793195A (fi) Foerfarande foer framstaellning av ett aemne med bakteriostatisk aktivitet
DE69028320D1 (de) Illudin-analoge, verwendet als antitumormittel
ATE15693T1 (de) Zellkultur-verfahren.
Loveren et al. Brief communication: In vitro activation of armed macrophages and the therapeutic application in mice
ES8604774A1 (es) Procedimiento de preparar agentes cosmeticos para el trata- miento de la piel
DK0538330T3 (da) Beta-Alethin-anvendelse til celledyrkning og terapi
Law et al. A unique tumor rejection antigen from the S91 murine malignant melanoma
PT72015B (en) Process for preparing "invitro" cultures of hepatitis b virus
SE8005921L (sv) Nya foreningar med karcinostatisk och immunostimulerande aktivitet samt forfarande for framstellning derav
Bilsel et al. Effect of defibrotide and endothelial cell growth supplement on human endothelial cells in culture
SU549106A1 (ru) Способ сохранени отдаленных гибридов
Ozato et al. Transfer of concanavalin A between responding lymphocytes and syngeneic stimulating cells in cell-mediated mitogenic response
ATE84077T1 (de) Satz und methode zur bestimmung der wucherungsaktivitaet von menschlichen tumoren.
Abe Establishment of a hamster lymphoma cell line
Vilcek CELL SUBSTRATES FOR BIOLOGICALS OTHER THAN VACCINES
IT1094286B (it) Procedimento per favorire la crescita di microorganismi fotosintetici e organismi simili
Storkus NK REGULATION OF B CELL DEVELOPMENT (NATURAL KILLER, IMMUNOREGULATION, DIFFERENTIATION)
SU1566533A1 (ru) Способ изготовления вакцины против пастереллеза птиц
JPS5550816A (en) Sterilization of culture medium for mushroom cultivation
PL285546A1 (en) Biological culture medium for cell cultures and method of culturing human keratocytes as well as proteinous concentrate

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8328 Change in the person/name/address of the agent

Free format text: MUELLER, SCHUPFNER & GAUGER, 80539 MUENCHEN